U.S., May 12 -- ClinicalTrials.gov registry received information related to the study (NCT07578571) titled 'A Phase 1 Study of IM-1617 in Participants With Advanced Cancer' on May 05.
Brief Summary: This study will test the safety and effectiveness of a drug called IM-1617 in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).
This study will have two parts. Part A will test increasing doses of IM-1617 to find out the safe dose and schedule of IM-1617 for participants. Part B will use the dose and schedule found in Part A to further study the safety of IM-1617 and if it works to treat solid tumor cancers.
Study Start Date...